Viewing Study NCT03755518

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:59 AM
Ignite Modification Date: 2026-03-14 @ 8:01 AM
Study NCT ID: NCT03755518
Status: TERMINATED
Last Update Posted: 2024-12-12
First Post: 2018-11-08
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
Sponsor: Celgene
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Primary Myelofibrosis View
None Post-Polycythemia Vera Myelofibrosis View
None Myelofibrosis View
None Post-essential Thrombocythemia Myelofibrosis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Myelofibrosis (MF) View
None Primary Myelofibrosis (PMF) View
None Post-Polycythemia Vera Myelofibrosis (Post-PV) View
None Post-essential thrombocythemia Myelofibrosis (Post-ET) View
None Myeloproliferative neoplasms (MPN) View